May Health raises $25m to develop ovarian therapy for women with PCOS
The Series B funding will help advance a study evaluating 'ovarian rebalancing' in women with infertility caused by PCOS.
Clinical-stage medical device company May Health has announced a $25 million Series B financing round. It was co-led by Bpifrance and Trill Impact with participation from founding investor Sofinnova Partners, as well as Avestria Ventures and Kidron Capital Assets LP.
Paris-based May Health was founded in 2017 and is dedicated to help those living with the endocrine disorder polycystic ovary syndrome (PCOS) - which affects 10% of women. PCOS is a serious and lifelong endocrine condition caused by hormone imbalance and the leading cause of female infertility.
May Health is developing Ovarian Rebalancing - a safe, straightforward treatment designed to restore women’s natural ovulation cycles. The one-time in-office procedure is designed to induce ovulation through targeted ablation of ovarian tissue using radiotherapy energy.
The latest round of investment will be used to support the company’s growth and advance its Ovarian Rebalancing therapy through the pivotal REBALANCE Study, evaluating its potential to address PCOS-related infertility. Ovarian Rebalancing would be an alternative treatment option to existing PCOS-related infertility such as IVF, Letrazole, Clomiphene Citrate and Gonadotrophins.
“For the millions of women living with PCOS, the physical and emotional impact of this condition is profound. From fertility challenges to emotional well-being and physical symptoms, women with PCOS need more viable treatment options,” said Anne Morrissey, CEO of May Health.
“We are thankful to Bpifrance and Trill Impact for co-leading this financing round, together with our founding investor Sofinnova Partners, and to our deep bench of supporters and advisors for their confidence in our team and growth strategy. We are eager to continue building on the positive results of our previous clinical studies as well as this financing milestone as we work to become a leader in global women’s health and PCOS-related infertility.”
The REBALANCE study
More than 15 fertility centers across the US will now participate in the clinical trial for the REBALANCE study. It is a multi-center, randomised pivotal study of the Ovarian Rebalancing therapy, designed to evaluate ovarian ablation and Ovarian Rebalancing in women aged 18-40 years old who have been diagnosed with PCOS and are resistant to or contraindicated to or decline first-line ovulation induction treatments.
“For years, women with PCOS who struggle with infertility have sought alternative treatment options that go beyond IVF and laparoscopic ovarian drilling,” said Dr. Robert Auerbach, OBGYN, chairman of the May Health board.
“Our team is working to develop a simple and safe procedure that can activate natural ovulation and help women regain their ability to grow their families. We’re thankful to our investment partners for their support and look forward to further research of Ovarian Balancing in the REBALANCE Study.”